Testing a medication to prevent weight loss during head and neck cancer treatment

This trial is testing whether olanzapine, a medication that can stimulate appetite, helps prevent weight loss in people undergoing chemotherapy and radiation for head and neck cancer. Half of participants will receive standard care alone, while the other half will take this medication daily alongside their standard care. The goal is to see if the medication helps patients maintain their weight and overall quality of life during this challenging treatment period.

Many people lose significant weight during chemotherapy and radiation for head and neck cancer because the treatments cause loss of appetite, nausea, and difficulty swallowing. Serious weight loss can weaken patients and affect their ability to complete treatment. This trial is exploring whether this medication can help solve that problem by boosting appetite and helping patients eat better.